Skip to main content

Table 2 FDA-approved drugs with a companion diagnostic

From: Next-generation sequencing to guide cancer therapy

Drug Disease DNA mutation Action
Imatinib, Dasatinib, Nilotinib, Bosutinib Chronic myelogenous leukemia BCR-ABL1 fusion Indication for therapy
Ponatinib Chronic myelogenous leukemia BCR-ABL1 fusion Only indicated for T315I mutations
T315I resistance mutation
Erlotinib, Afatinib Lung adenocarcinoma EGFR Indication for therapy
Exon 19 deletions
L858R
Vemurafenib, Dabrafenib Melanoma BRAF V600E Indication for therapy
Tramatenib Melanoma BRAF V600E/K Indication for therapy
Crizotinib Lung cancer ALK gene fusions Indication for therapy
Cetuximab Colon cancer KRAS codon 12, 13 Contraindication to therapy
Olaparib Ovarian cancer BRCA1 and BRCA2 mutations Indication for therapy
  1. Each drug has a specific genomic result that is part of its indication for use. FDA Food and Drug Administration